Thromboplastin Plasma Method
Thromboplastin Plasma Method - Related Videos
03:59
miRNA Extraction: A Method to Extract miRNA from Plasma Sample
0 Views •
2023
MicroRNAs (miRNAs) are tissue specific, small, non-coding RNAs regulating gene expression, and could represent ideal candidates for early detection of lung cancer. In the featured protocol, we will isolate microRNA from patient blood samples for early lung cancer screening.
08:42
How to Ignite an Atmospheric Pressure Microwave Plasma Torch without Any Additional Igniters
0 Views •
Cited by 26 •
2015
This movie shows how an atmospheric plasma torch can be ignited by microwaves with no additional igniters and provides a stable and continuous plasma operation suitable for plenty of applications.
07:54
Experimental Methods of Dust Charging and Mobilization on Surfaces with Exposure to Ultraviolet Radiation or Plasmas
0 Views •
Cited by 2 •
2018
Dust charging and mobilization is demonstrated in three experiments with exposure to thermal plasma with beam electrons, beam electrons only, or ultraviolet (UV) radiation only. These experiments present the advanced understanding of electrostatic dust transport and its role in shaping the surfaces of airless planetary bodies.
08:36
An Atmospheric Pressure Plasma Setup to Investigate the Reactive Species Formation
0 Views •
Cited by 20 •
2016
An experimental setup was created for the helium-operated kHz frequency plasma jet. The setup includes a cage for the plasma power supply and jet and an in-house built reactor to monitor plasma-induced reactive species without the interference of the ambient atmosphere.
06:46
Applying X-ray Imaging Crystal Spectroscopy for Use as a High Temperature Plasma Diagnostic
0 Views •
Cited by 4 •
2016
X-ray spectra provide a wealth of information on high temperature plasmas. This manuscript presents the operation of a high wavelength resolution spatially imaging X-ray spectrometer used to view hydrogen- and helium-like ions of medium atomic number elements in a tokamak plasma.
FAQs
Tissue thromboplastin contributes tissue factor and phospholipids, creating the reagent environment that initiates coagulation through the extrinsic pathway. Added calcium replaces the ion removed during plasma citration, allowing the downstream reactions to proceed. The measured interval until fibrin clot formation therefore reflects the combined performance of the extrinsic and common pathways rather than a single coagulation factor.
The assay result depends on the activity of factors I, II, V, VII, and X. Factor VII represents the extrinsic pathway component, while factors I, II, V, and X participate in the common pathway leading to fibrin formation. Changes affecting any of these components can alter clotting time, making the measurement useful for comparing overall pathway activity.
Citrated plasma preserves the sample in a state where coagulation does not proceed until the test reaction begins. Because citrate removes calcium, the assay restores that required ion at a defined stage by adding calcium with tissue thromboplastin. This design links the observed clotting time to the test reaction and supports comparisons of coagulation function between experimental groups.
The procedure begins with citrated plasma, followed by addition of tissue thromboplastin and calcium. The sample is then observed or assessed until a fibrin clot forms, and the clotting time is recorded. Comparing these measurements across samples or experimental groups allows investigators to identify differences in extrinsic and common pathway activity without treating the result as an isolated factor measurement.
Cancer studies can use the assay to characterize changes in coagulation associated with tumor biology. Measuring clotting profiles across experimental groups may reveal differences in blood-clotting function and help investigators examine mechanisms linked to thrombosis risk. The approach is especially useful when the research question concerns how disease-related changes influence the extrinsic and common coagulation pathways.
Researchers can compare clotting measurements before or across experimental conditions to assess whether an anticancer intervention changes coagulation behavior. A shift in clotting time may indicate altered activity within the factor-dependent pathways measured by the assay. In cancer research, these results can connect treatment effects with hemostatic changes and support broader studies of coagulation mechanisms and thrombosis risk.